SCHEMBL2628026

SCHEMBL2628026

N#CC(CCOCc1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TACR1 P25103 2/20 0.42
NAAA Q02083 1/20 0.41
GHSR Q92847 2/20 0.40
CYP3A4 P08684 2/20 0.40
MPO P05164 1/20 0.40
TPO P07202 1/20 0.40
SGMS2 Q8NHU3 1/20 0.39
CTSL P07711 3/20 0.38
CTSB P07858 2/20 0.38
CTSK P43235 2/20 0.38
CYP2C19 P33261 2/20 0.38
CTSS P25774 1/20 0.38
ESR1 P03372 3/20 0.38
ESR2 Q92731 3/20 0.38
MAOB P27338 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2628022 0.86 CNR2 (0.39) TSHRHTTSMN1; SMN2TACR1CYP3A4
SCHEMBL13720747 0.85 CA1 (0.41) TSHRHTTSMN1; SMN2TACR1GHSR
SCHEMBL10657232 0.78 TSHR (0.47) TSHRHTTSMN1; SMN2TACR1NAAA
SCHEMBL30868576 0.78 TSHR (0.47) TSHRHTTSMN1; SMN2NAAACTSL
SCHEMBL14139311 0.78 TSHR (0.47) TSHRHTTSMN1; SMN2NAAACTSL
SCHEMBL2633190 0.78 TSHR (0.39) TSHRHTTCTSLCTSSMEN1
SCHEMBL1554435 0.77 PBRM1 (0.41) TSHRCYP3A4CYP2C19ESR1ESR2
SCHEMBL1343597 0.77 ACP3 (0.44) TSHRCYP3A4CYP2C19ESR1ESR2
SCHEMBL3648830 0.75 TSHR (0.52) TSHRHTTSMN1; SMN2NAAACYP3A4
SCHEMBL4022770 0.75 CA1 (0.54) TSHRTACR1CYP3A4CTSLCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357809-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-22 US disclosed
US-20120094983-A1 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-19 US disclosed
US-7915410-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-20070082909-A1 Acyclic Ikur inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082909-A1 Acyclic Ikur inhibitors KCNH2, KCNJ2, KCNH3 TSHR 566/4885HTT 3479/4885SMN1; SMN2 3472/4885
US-20120094983-A1 ACYCLIC IKUR INHIBITORS KCNH2, KCNJ2, KCNH3 TSHR 566/4885HTT 3479/4885SMN1; SMN2 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.